Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma - PubMed (original) (raw)

Comparative Study

. 2021 Nov 1;43(11):781-787.

doi: 10.1097/DAD.0000000000001901.

Affiliations

Comparative Study

Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma

Keisuke Goto et al. Am J Dermatopathol. 2021.

Abstract

Distinguishing porocarcinoma from squamous cell carcinoma (SCC) is clinically significant; however, differential diagnosis can often be challenging. This study sought to confirm the diagnostic utility of cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 immunohistochemistry in distinguishing porocarcinoma from SCC. Immunohistochemical analysis of cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 in 14 porocarcinomas and 22 SCCs was performed; the extents and intensities of expression of these markers were recorded. The statistical associations of the immunoexpression between porocarcinoma and SCC were analyzed using the Pearson χ2 test. Cytokeratin 19 was positive in 13 (92.9%) of 14 porocarcinomas, and for all the positive cases, staining was strong and evident in >20% of the tumor cells. By contrast, 9 (40.9%) of 22 SCCs expressed cytokeratin 19 (P = 0.0018), of which 6 showed extremely focal (≤10% of the tumor cells) expression. Of the 14 porocarcinomas, 11 (78.6%) cases showed c-KIT positivity, whereas only 3 of 22 SCCs (13.6%) expressed c-KIT focally (P = 0.0001). In addition, BerEP4 immunostaining differed between porocarcinomas and SCCs (57.1% vs. 9.1%, respectively; P = 0.0017). However, no significant difference between the groups was reported in terms of GATA3 expression (57.1% vs. 72.7%, respectively; P = 0.3336). NUTM1 was expressed in 4/14 (28.6%) porocarcinomas but not in the SCCs. Immunohistochemistry for cytokeratin 19, c-KIT, and BerEP4 could be helpful in distinguishing porocarcinomas from SCCs. In addition, NUTM1 immunoexpression is highly specific, although not sensitive, to porocarcinomas. GATA3 immunohistochemistry has no meaningful implications in the differential diagnosis of porocarcinoma and SCC.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

Cited by

References

    1. Elder DE, Massi D, Scolyer RA, et al. eds. WHO Classification of Skin Tumours. Lyon, France: IARC Press; 2018.
    1. Mahalingam M, Richards JE, Selim MA, et al. An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma. Hum Pathol. 2012;43:1265–1272.
    1. Mahomed F, Blok J, Grayson W. The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. J Clinpathol. 2008;61:361–365.
    1. Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710–720.
    1. Shinohara J, Koga H, Uhara H, et al. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. J Dermatol. 2007;34:516–522.

Publication types

MeSH terms

Substances

LinkOut - more resources